Abstract

Azenta will report fiscal Q1 results on February 04, 2026 Pre-Market; this preview compiles market estimates and institutional commentary to frame expectations for revenue, margins, and adjusted EPS, along with segment dynamics and consensus tone.

Market Forecast

Consensus for the current quarter points to revenue of USD 147.16 million, a gross profit margin around 42.76%, a net profit margin near 31.98%, and adjusted EPS of USD 0.14, with estimated year-over-year growth of 0.67% in revenue and 141.08% in EPS. The company’s core mix remains services and products, with services expected to anchor stability while products provide cyclical upside amid equipment and consumables demand. The most promising segment is services, with last quarter revenue of USD 111.17 million; year-over-year growth was negative last quarter, but services continue to show resilient demand across biorepository solutions and sample management.

Last Quarter Review

Azenta posted last quarter revenue of USD 159.19 million, a gross profit margin of 42.76%, GAAP net profit attributable to the parent company of USD 50.84 million, a net profit margin of 31.98%, and adjusted EPS of USD 0.21, with year-over-year adjusted EPS growth of 16.67%. A notable highlight was EBIT of USD 9.09 million, which exceeded the previously compiled estimate of USD 7.28 million. Main business highlights showed services revenue of USD 111.17 million and products revenue of USD 48.02 million, reflecting the ongoing predominance of services in the revenue mix.

Current Quarter Outlook

Services Business

Services remain the company’s core revenue driver, underpinned by long-duration contracts, high switching costs, and embedded workflows in biorepository and enterprise sample management. This quarter, the forecasted total revenue implies services will continue to contribute the majority of the top line, benefiting from stable utilization and expanding enterprise programs. Pricing discipline and mix could sustain gross margin performance near the low-40% range, with operational efficiency initiatives supporting EBIT leverage. Key watch items include service renewal rates and any signals of expanded multi-year agreements, which would reinforce visibility into sequential performance.

Products Business

Products revenue is meaningfully smaller than services but can drive incremental growth via equipment placements and related consumables. The segment’s contribution depends on the cadence of capital purchases across biopharma and academic customers, as well as the rate of add-on automation deployments. With adjusted EPS expected at USD 0.14 and EBIT estimate at USD 4.96 million, any upside in products shipments would translate quickly to operating leverage given fixed cost absorption. Investors should monitor order intake trends, lead times, and commentary on supply chain and pricing, which together influence margin dispersion within the quarter.

Stock Price Drivers This Quarter

The stock’s near-term reaction will be sensitive to the interplay of revenue growth and margin durability. EPS guidance and commentary on demand momentum across services contracts could shape the outlook for multi-quarter earnings power, while clarity on products backlog conversion will determine whether revenue modestly outperforms estimates. A sustained gross margin near 42.76% would support confidence in cost discipline; conversely, any mix shift away from higher-margin services could pressure net profitability. The degree of sequential improvement versus last quarter’s strong adjusted EPS print of USD 0.21 will likely frame the market’s interpretation of growth sustainability.

Analyst Opinions

The majority of collected institutional views indicate a moderately constructive stance into the print, citing stable services demand and improving operating efficiency as supports for EPS resilience. Commentary highlights the balance of recurring service revenue and incremental product placements, suggesting balanced risk with a bias toward meeting or modestly exceeding conservative revenue expectations near USD 147.16 million. Analysts emphasize the importance of services contract renewals and margin execution, noting that visibility into backlog and program expansion is pivotal to sustaining EPS growth of 141.08% year over year on the current-quarter estimate. The prevailing view expects steady operational performance and disciplined capital allocation to underpin a stable margin profile, with upside contingent on healthier product order conversion and continued services pipeline expansion.